1Biotech & Biopharma
We invest in novel science seeking breakthroughs that address critical unmet medical needs, have the potential to change the practice of medicine whilst generating attractive investor returns.
We are venture focused and make initial investments at levels from seed capital through early clinical development stages of truly innovative medicines and platform technologies. We have a long history of building high value, successful new companies developing transformational new medicines, and bringing drugs from discovery to market.
We can transform early science into leading companies and employ a company creation approach to biotech investing with many of these companies being created in house. We always welcome the opportunity to talk to entrepreneurs so please get in touch.
We seek companies that innovate with vision and execute with conviction to solve the most pressing problems in our health care delivery system. We back experienced and entrepreneurial executives to create industry-leading companies.
Leveraging the technology and data infrastructure implemented over the past decade, the future holds unlimited opportunities to mend structural deficiencies in the healthcare system. Innovation drives the shift of care to lower-cost settings, easier patient access, de-stigmatization of mental health treatment, democratization of clinical trials, and increasingly holistic care infrastructure.
Our strategy is focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges.
The future of medtech resides in the shifts from intervention to prevention, invasive to non-invasive and hospitals to the home. We are focused on technologies that can expand patient access via telehealth or utilize monitoring technologies to otherwise extend more effective management of chronic disease to the least intensive setting and ultimately the home.
Our portfolio companies will help reduce the increasing burden on clinicians and drive down healthcare operating costs. As a leader in early-stage medical device innovation, we expect our entrepreneurs, our investments, and our portfolio companies will define new therapies and create new care settings.
The portfolio is focused on companies aiming to develop breakthrough treatments for conditions that affect millions of people, including cancer, rare diseases, infectious diseases, and cardiovascular disease.
For more information, please contact Mr. Shu Joshi (firstname.lastname@example.org)